Controls serum phosphorus. ANDA 200959, held by Quagen. Sevelamer Carbonate.
As of Nov 16, 2026, ANDA 200959 (Sevelamer Carbonate), held by Quagen, was first approved by FDA on Mar 20, 2018, with 1 approved supplement and 0 published complete response letters.
Sevelamer carbonate tablets are indicated for the control of serum phosphorus in adults and children 6 years of age and older with chronic kidney disease (CKD) on dialysis.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Mar 20, 2018 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Sevelamer Carbonate800MG · tablet;oral | Sevelamer Carbonate | Rx |
| Apr 25, 2022 | Supplement 3Labeling · Standard review | Approved | None posted |
| Mar 20, 2018 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters